Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC).

Q: What does this research mean for the field?

High expression of chemokines CXCL9 and CXCL10 are independent predictors of pembrolizumab response in triple-negative breast cancer and can identify additional patients who may benefit when integrated with PD-L1 and TMB. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Shipra Gandhi; Sachin Kumar Deshmukh; Madison T. Canning; Dario Trapani; Sharon Wu; José Pablo Leone; Kevin Kalinsky; Evanthia T. Roussos Torres; Sunil S. Badve; Mayukhmala Jana; Anant Madabhushi; Sahar Almahfouz; Hilmi Al-Shakshir; Maryam B. Lustberg; Kazuaki Takabe; G Curigliano; George W. Sledge; Pawel Kalinski

doi:10.1200/jco.2026.44.16_suppl.1125

Key Points

This research aims to assess whether chemokines CXCL9 and CXCL10 can improve the prediction of pembrolizumab benefit in triple-negative breast cancer compared to established biomarkers PD-L1 and TMB.
Analyzed 3662 TNBC tumors through next-generation sequencing.
Classified chemokine expression as high or low based on the 50th percentile.
Evaluated associations using chi-square and Mann-Whitney U tests with multiple comparisons adjustment.
High CXCL9/10 expression correlates with improved mOS: 24.5 months vs 15.8 months for CXCL9, and 23.4 months vs 17 months for CXCL10, all p<0.05.
PD-L1 positive tumors showed improved mOS of 24.3 months compared to 18.6 months for PD-L1 negative (p=0.007).
CXCL9 and CXCL10 remain independent predictors of pembrolizumab benefit with HRs of 0.67 (95% CI 0.54-0.83) and 0.79 (95% CI 0.64-0.97) respectively, all p<0.05.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Evaluates CXCL9/10’s ability to predict pembrolizumab benefit in TNBC, suggesting new biomarker potential.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gandhi et al. (2026) studied this question.

synapsesocial.com/papers/6a192f07fab5b468c441849b https://doi.org/10.1200/jco.2026.44.16_suppl.1125

View at Publisher

Ask AI

Bookmark

Share

Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC).

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Real-world evaluation of CXCL9/10 with PD-L1 and TMB as predictors of pembrolizumab benefit in triple-negative breast cancer (TNBC).

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading